Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163481 | 0.91 | ADORA2A (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3169774 | 0.89 | ADORA2A (0.43) | ADORA2BADORA3ADORA2AADORA1MAPT | |
| SCHEMBL3175769 | 0.88 | ADORA2A (0.45) | ADORA2BADORA3ADORA2AADORA1MAPT | |
| SCHEMBL3162937 | 0.87 | ADORA2A (0.46) | ADORA2BADORA3ADORA2AADORA1MAPT | |
| SCHEMBL3165495 | 0.87 | TDP1 (0.45) | ADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL3166225 | 0.86 | ADORA2A (0.45) | ADORA2BADORA3ADORA2AADORA1MAPT | |
| SCHEMBL3174594 | 0.86 | ADORA2A (0.45) | ADORA2BADORA3ADORA2AADORA1MAPT | |
| SCHEMBL3162870 | 0.86 | NPSR1 (0.44) | ADORA2BADORA3ADORA2AADORA1POLB | |
| SCHEMBL3171546 | 0.86 | ADORA2A (0.40) | ADORA2BADORA3ADORA2AADORA1POLB | |
| SCHEMBL3163330 | 0.86 | NPSR1 (0.48) | POLBNPSR1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465631-B1 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| EP-1465631-A4 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1465631-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003053366-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | GRIN2D 1112/4885GRIN3B 1029/4885GRIN1 2234/4885 |
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | GRIN2D 594/4885GRIN3B 403/4885GRIN1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.